Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $9.80 Consensus Target Price from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.80.

A number of equities research analysts have weighed in on the stock. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partners raised their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $5.09 on Tuesday. The firm has a 50-day simple moving average of $4.99 and a two-hundred day simple moving average of $3.99. The firm has a market cap of $464.10 million, a P/E ratio of -11.31 and a beta of 2.82. Aquestive Therapeutics has a fifty-two week low of $1.84 and a fifty-two week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter in the previous year, the business earned ($0.03) earnings per share. On average, equities research analysts predict that Aquestive Therapeutics will post -0.47 EPS for the current year.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after purchasing an additional 1,353,518 shares during the period. Blue Owl Capital Holdings LP grew its holdings in Aquestive Therapeutics by 30.3% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after buying an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Aquestive Therapeutics during the second quarter valued at approximately $594,000. Chartwell Investment Partners LLC purchased a new position in shares of Aquestive Therapeutics in the third quarter worth $535,000. Finally, Lazard Asset Management LLC boosted its position in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.